카지노 바카라 receives Korean approval for global Phase 3 clinical trial of 'Keytruda biosimilar'

[by Lee, Young Sung] 카지노 바카라 announced on April 28 that it has received approval from the Ministry of Food and Drug Safety for the Phase 3 clinical trial plan for 'CT-P51,' a biosimilar candidate to Keytruda. This study will be conducted as a global phase 3 clinical trial, with Korea included among the approved sites.

Through this phase 3 clinical trial, 카지노 바카라 will evaluate the efficacy and safety of 'CT-P51' compared to 'Keytruda,' in combination with platinum-pemetrexed chemotherapy, in 606 patients with metastatic non-squamous non-small cell lung cancer who have not received prior treatment. The study is expected to be conducted over a period of approximately two years.

"We anticipate expanding our market presence and increasing sales by obtaining approval for all indications, including not only metastatic non-squamous non-small cell lung cancer but also other types of non-small cell lung cancer for which the original drug has been approved," a 카지노 바카라 official said.